Skip to main content
. Author manuscript; available in PMC: 2013 Aug 15.
Published in final edited form as: Circ Res. 2013 May 21;113(3):288–300. doi: 10.1161/CIRCRESAHA.113.300929

Figure 8.

Figure 8

HIF-1α silencing and IGF-1 neutralization reduce the therapeutic potential of shPHD2-GFP-ADSCs on infarcted hearts. A: The percentage of survived ADSCs out of total transplanted ADSCs at 48 hours after ADSCs transplantation. B: TUNEL+ cardiomyocytes in infarct border zone at 48 hours after ADSCs transplantation. CE: LV infarct size (C), EF% (D) and FS% (E) at 4 weeks after MI. For A–E: N=6. * p<0.05 vs. GFP-ADSCs; # p<0.05 vs. shPHD2-GFP-ADSCs.